A Screening Test for Renovascular Hypertension by Means of Orally Active Angiotensin I Converting Enzyme Inhibitor, Captopril (SQ 14225)

Yutaka Imai; Keishi Abe; Yoichi Otsuka; Yutaka Sakurai; Kaoru Yoshinaga

doi:10.1620/tjem.131.311

A Screening Test for Renovascular Hypertension by Means of Orally Active Angiotensin I Converting Enzyme Inhibitor, Captopril (SQ 14225)

Yutaka Imai, Keishi Abe, Yoichi Otsuka, Yutaka Sakurai, Kaoru Yoshinaga

Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Orally active converting enzyme inhibitor (Captopril, SQ 14225) was administered in a dose of 50 mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II) and 8 renovascular hypertensive patients (Group III). In Group III, 5 of 8 patients had control plasma renin activity (PRA) similar to those in Groups I and II patients, but the PRA response to the administration of Captopril was greater in 7 of 8 patients than that in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renal aplasia. It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.

Original language	English
Pages (from-to)	311-312
Number of pages	2
Journal	the tohoku journal of experimental medicine
Volume	131
Issue number	3
DOIs	https://doi.org/10.1620/tjem.131.311
Publication status	Published - 1980

Keywords

Captopril
renin
renovascular hypertension
screening test

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Access to Document

10.1620/tjem.131.311

Fingerprint Dive into the research topics of 'A Screening Test for Renovascular Hypertension by Means of Orally Active Angiotensin I Converting Enzyme Inhibitor, Captopril (SQ 14225)'. Together they form a unique fingerprint.

Cite this

@article{22ef6db03a3f477d886b8859f261a2c2,

title = "A Screening Test for Renovascular Hypertension by Means of Orally Active Angiotensin I Converting Enzyme Inhibitor, Captopril (SQ 14225)",

abstract = "Orally active converting enzyme inhibitor (Captopril, SQ 14225) was administered in a dose of 50 mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II) and 8 renovascular hypertensive patients (Group III). In Group III, 5 of 8 patients had control plasma renin activity (PRA) similar to those in Groups I and II patients, but the PRA response to the administration of Captopril was greater in 7 of 8 patients than that in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renal aplasia. It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.",

keywords = "Captopril, renin, renovascular hypertension, screening test",

author = "Yutaka Imai and Keishi Abe and Yoichi Otsuka and Yutaka Sakurai and Kaoru Yoshinaga",

year = "1980",

doi = "10.1620/tjem.131.311",

language = "English",

volume = "131",

pages = "311--312",

journal = "Tohoku Journal of Experimental Medicine",

issn = "0040-8727",

publisher = "Tohoku University Medical Press",

number = "3",

}

TY - JOUR

T1 - A Screening Test for Renovascular Hypertension by Means of Orally Active Angiotensin I Converting Enzyme Inhibitor, Captopril (SQ 14225)

AU - Imai, Yutaka

AU - Abe, Keishi

AU - Otsuka, Yoichi

AU - Sakurai, Yutaka

AU - Yoshinaga, Kaoru

PY - 1980

Y1 - 1980

N2 - Orally active converting enzyme inhibitor (Captopril, SQ 14225) was administered in a dose of 50 mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II) and 8 renovascular hypertensive patients (Group III). In Group III, 5 of 8 patients had control plasma renin activity (PRA) similar to those in Groups I and II patients, but the PRA response to the administration of Captopril was greater in 7 of 8 patients than that in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renal aplasia. It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.

AB - Orally active converting enzyme inhibitor (Captopril, SQ 14225) was administered in a dose of 50 mg to 12 normotensive subjects (Group I), 26 essential hypertensive patients (Group II) and 8 renovascular hypertensive patients (Group III). In Group III, 5 of 8 patients had control plasma renin activity (PRA) similar to those in Groups I and II patients, but the PRA response to the administration of Captopril was greater in 7 of 8 patients than that in Groups I and II. These 7 patients had either bilateral or unilateral main renal artery stenosis. Captopril caused no increase in PRA in the remaining 1 who had unilateral renal artery stenosis with contralateral renal aplasia. It is concluded that this provocation test is useful as a screening procedure for the diagnosis of renovascular hypertension.

KW - Captopril

KW - renin

KW - renovascular hypertension

KW - screening test

UR - http://www.scopus.com/inward/record.url?scp=0019308316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019308316&partnerID=8YFLogxK

U2 - 10.1620/tjem.131.311

DO - 10.1620/tjem.131.311

M3 - Article

C2 - 6998048

AN - SCOPUS:0019308316

VL - 131

SP - 311

EP - 312

JO - Tohoku Journal of Experimental Medicine

JF - Tohoku Journal of Experimental Medicine

SN - 0040-8727

IS - 3

ER -